Rash News and Research

RSS

Lab results change in consistent ways during the course of Kawasaki disease

Children with Kawasaki disease show a pattern of changing laboratory test results as the disease runs its course, according to a study in the December issue of The Pediatric Infectious Disease Journal.

15 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Tips for parents to protect children from holiday dangers

The holidays are an exciting and busy time of year as parents race to finish the shopping, decorating and baking. As the number of days left in the calendar year winds down, be sure to allow plenty of time in that hectic schedule for playing with your child and sharing holiday traditions as a family. Nationwide Children's Hospital reminds parents to keep alert to various holiday dangers.

12 Dec 2011

Breast cancer hope with new drug and new combination regimens

last week at the San Antonio Breast Cancer Symposium, researchers announced encouraging results from studies of two cancer medications that appeared to keep breast cancer from advancing.

11 Dec 2011

FDA approves changes to REMS for Nplate and Promacta

The approval of changes to the Risk Evaluation and Mitigation Strategies (REMS) for both Nplate (romiplostim) and Promacta (eltrombopag) was announced by the U.S. Food and Drug Administration.

7 Dec 2011

Measles raises its head again in Europe after years of suppression: Report

According to a new report last Thursday, measles incidence is on the rise in Europe following decades of decline. Up to October European health officials reported more than 26,000 measles cases this year and nine deaths.

5 Dec 2011

University of Illinois Hospital prescribes Tumor Treating Fields therapy for recurrent GBM

The University of Illinois Hospital is the first center in North America to prescribe a new FDA-approved treatment for patients with the most common and aggressive type of brain tumor, glioblastoma multiforme, or GBM.

3 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

Shots reduce risk of chicken pox

Infants below the age of one may be too young to get the chicken pox vaccine but far fewer of them got the itchy rash after the U.S. started routinely vaccinating older children in 1995, according to a new study.

29 Nov 2011

NHS Choices launches new penis health gallery for men

Could you spot genital warts from herpes, or crabs from a rash? Now you can. NHS Choices, the health information website for the NHS, has launched a new penis health gallery to help men spot common problems with their penises.

16 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

Long-range wind transport of an infectious agent may cause KD

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. In fact, if not diagnosed or treated in time, it can lead to irreversible heart damage. After 50 years of research, including genetic studies, scientists have been unable to pinpoint the cause of the disease.

10 Nov 2011

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

8 Nov 2011

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA.

7 Nov 2011

Experts share latest buzz on allergies to alcohol and tobacco

While the health benefits of drinking wine in moderation continue to make news, for some with allergies even a glass a day may be difficult to swallow. At the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Nov. 3-8, allergists share the latest buzz on allergies to alcohol and tobacco.

7 Nov 2011

Study finds pregnancy safe for 80% of women with lupus

Promising research led by investigators at Hospital for Special Surgery may offer hope for women with lupus who once thought that pregnancy was too risky.

7 Nov 2011

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE (bortezomib) for Injection, which updates the label to include additional long-term overall survival (OS) data from the VISTA trial.

2 Nov 2011

Study evaluates availability of information about cosmetic ingredients for celiac patients

The lack of readily available information about cosmetic ingredients may cause patients with celiac disease who use lip, facial or body products to unknowingly expose themselves to gluten—an ingredient they need to avoid, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

YM BioSciences announces results of nimotuzumab Phase II study on DIPG

YM BioSciences Inc. today announced that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG) were reported at the 43rd Congress of the International Society of Paediatric Oncology (SIOP) conference being held in Auckland, New Zealand.

31 Oct 2011